Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 77

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in July 2017. The industry reported 314 deals worth USD29.5 billion in July 2017, compared to 392 deals worth USD31.5 billion in June 2017. The oncology therapeutics market remained at the top in deal activity in July 2017 with 104 deals. In second place, infectious disease therapeutics market reported 60 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD203.7m as upfront payments in July 2017, compared to USD130m in June 2017. The number of deals in North America decreased to 203 in July 2017 from 254 in June 2017.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the six months.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Parkinson’s Disease: Epidemiology Forecast to 2026

Parkinson's Disease: Epidemiology Forecast to 2026 Summary Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly, affecting 1-2% of individuals ages 65 years and older worldwide. PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression. Age, genetics, sex, and environmental exposure to pesticides increase the risk of developing PD. Conditions such as depression and anxiety have been identified as comorbidities in PD. For this analysis, GlobalData epidemiologists utilized peer-reviewed studies to construct the 10-year epidemiological forecast for the diagnosed prevale......
$3995

Paralysis Global Clinical Trials Review, H1, 2018

Paralysis Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Paralysis Global Clinical Trials Review, H1, 2018" provides an overview of Paralysis clinical trials scenario. This report provides top line data relating to the clinical trials on Paralysis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H1, 2018

Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H1, 2018" provides an overview of Pelvic Inflammatory Disease (Pelvic Infections) clinical trials scenario. This report provides top line data relating to the clinical trials on Pelvic Inflammatory Disease (Pelvic Infections). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Gl......
$2500

Otitis Media Global Clinical Trials Review, H1, 2018

Otitis Media Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Otitis Media Global Clinical Trials Review, H1, 2018" provides an overview of Otitis Media clinical trials scenario. This report provides top line data relating to the clinical trials on Otitis Media. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Paraplegia Global Clinical Trials Review, H1, 2018

Paraplegia Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Paraplegia Global Clinical Trials Review, H1, 2018" provides an overview of Paraplegia clinical trials scenario. This report provides top line data relating to the clinical trials on Paraplegia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are ......
$2500

Pemphigus Global Clinical Trials Review, H1, 2018

Pemphigus Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Pemphigus Global Clinical Trials Review, H1, 2018" provides an overview of Pemphigus clinical trials scenario. This report provides top line data relating to the clinical trials on Pemphigus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Ovarian Cancer Global Clinical Trials Review, H1, 2018

Ovarian Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Ovarian Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Parasitic Diseases Global Clinical Trials Review, H1, 2018

Parasitic Diseases Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Parasitic Diseases Global Clinical Trials Review, H1, 2018" provides an overview of Parasitic Diseases clinical trials scenario. This report provides top line data relating to the clinical trials on Parasitic Diseases. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Pemphigus Vulgaris Global Clinical Trials Review, H1, 2018

Pemphigus Vulgaris Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Pemphigus Vulgaris Global Clinical Trials Review, H1, 2018" provides an overview of Pemphigus Vulgaris clinical trials scenario. This report provides top line data relating to the clinical trials on Pemphigus Vulgaris. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Ovarian Disease Global Clinical Trials Review, H1, 2018

Ovarian Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Ovarian Disease Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy